相关实验视频

Updated: Jul 10, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

神经生长因子,抗微生物和化疗:结合治疗质母细胞瘤以提高其有效性

Alexandr Chernov¹, Igor Kudryavtsev¹, Aleksei Komlev¹

¹Institute of Experimental Medicine, WCRC "Center for Personalized Medicine", Saint-Petersburg 197022, Russia.

|November 25, 2023

概括

神经生长因子 (NGF) 和抗菌LL-37和PG-1对质母细胞瘤具有强大的抗癌作用. 保护素-1 (PG-1) 与埃托胺的组合协同诱导了亡,提供了一个有前途的质母细胞瘤治疗方法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑癌.
传统化疗在治疗GBM方面存在局限性.
需要新的治疗策略来改善GBM治疗结果.

研究的目的:

为了研究神经生长因子 (NGF),cathelicidin (LL-37) 和protegrin-1 (PG-1) 与质母细胞瘤U251细胞中的化疗剂的联合抗癌作用.
评估这些组合的潜力,以克服传统化疗的局限性.
确定这些组合对质母细胞瘤细胞活力和亡的协同或对抗作用.

主要方法:

使用MTT测定来评估细胞活力和确定细胞毒性影响 (IC50值).
组合指数 (CI) 方法用于分析药物协同作用或对抗作用.
使用卡斯帕-3活性测定和流动细胞计 (酸和YO-PRO-1染色) 来评估亡.

主要成果:

NGF,LL-37和PG-1对U251质瘤细胞表现出显著的细胞毒性作用.
结合PG-1和etoposide在诱导U251细胞的亡方面表现出协同作用.
似乎PG-1和etoposide的组合诱导了卡斯巴酶独立的亡.

结论:

NGF,LL-37和PG-1是质母细胞瘤治疗方案的有希望的候选药物.
PG-1和etoposide的协同组合提供了一种潜在的治疗方法,可以克服传统治疗的局限性.
这种组合策略代表了推动质母细胞瘤治疗的有希望的途径.

关键词:

抗微生物类的抗微生物.化学疗法化疗化疗质母细胞瘤 (glioblastoma) 是一种神经生长因子的神经生长因子有协同效应的效应.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...